Summary
This 8-K filing from Cardinal Health, Inc. (CAH) on July 10, 2009, announces a significant operational development related to its subsidiary, CareFusion Corporation. The key information for investors is the resumption of shipping for Alaris® PC units and Alaris® PCA modules. This resumption is directly tied to the receipt of FDA 510(k) clearance for a software correction that addresses a previously identified risk. The risk involved potential infusion dosage inaccuracies when the Alaris PCA module is used with specific software versions of the Alaris PC Unit under a particular sequence of events. The clearance and subsequent resumption of shipping are positive indicators for CareFusion's business operations and its planned spin-off, which was expected to result in a publicly traded entity. This resolution of a product safety concern and the associated shipping hold is crucial for revenue generation and investor confidence in the upcoming separation.
Key Highlights
- 1CareFusion Corporation, a subsidiary of Cardinal Health, Inc., will resume shipping Alaris® PC units and Alaris® PCA modules.
- 2The resumption of shipping is contingent on receiving FDA 510(k) clearance for a software correction.
- 3The software correction addresses a potential risk of incorrect infusion doses with Alaris PCA modules when used with specific Alaris PC Unit software versions (8 through 9.1) under a defined sequence of events.
- 4Cardinal Health had previously placed a hold on shipping these products pending the software correction.
- 5FDA 510(k) clearance for the software correction was received on July 9, 2009.
- 6This development is positive for CareFusion's operational continuity and its upcoming spin-off.